Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for treating autoimmune diseases, particularly in systemic lupus erythematosus (SLE). However, CAR T-cell therapy for pediatric patients with SLE remains unexplored. Herein, we present a compelling investigation of two pediatric patients with refractory SLE who underwent infusion of CD19-targeted CAR T-cells. Patients 1 and 2 tolerated the CAR T-cell therapy well, which demonstrated remarkable efficacy after five and four months, respectively.